Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Breast Cancer: early-phase trial registry
423 of 1,251 indexed Breast Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1 of 28,963 conditions by registered trial count.
1,251 US clinical trials · 423 currently recruiting · #1 of 28,963 conditions by registered trial count
Breast Cancer: 1,251 US clinical trials tracked, 423 recruiting.
Breast Cancer is the subject of 1,251 registered US clinical trials on ClinicalTrials.gov, 423 of them currently open to new participants. 120 are in Phase 3-4 (later-stage) and 491 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 98 of these trials.
Open enrollment, early-phase tilt
Breast Cancer has 1,251 registered US clinical trials, 423 of them open to new participants right now, about 34% of the total.
- 423
- recruiting participants now
- 34%
- of trials open to enrollment
- 120
- in Phase 3-4 (later-stage)
- 98
- top sponsor: Memorial Sloan Kettering Cancer Center
Corpus placement: #1 of 28,963 conditions by registered trial count on ClinicalTrials.gov-derived indexes. Registry reference only, not medical advice.
Key findings
What ClinicalTrials.gov does not surface for Breast Cancer on its own pages , computed from the registry mirror as of 2026-07-11. Each line carries its own denominator so it can be quoted as it stands.
-
Breast Cancer is recruiting below its size-band peers.
423 of 1,251 indexed trials (33.8%) are open to enrollment, against a 37.2% average across 135 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Breast Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 98 of 1,251 trials (7.8%). 367 distinct sponsors appear on at least one study for this condition label.
-
Typical Breast Cancer enrolment sits around 90 participants.
Median target enrolment is 90 among the 1,225 trials that report a genuine target (sentinel values excluded). 630 of those (51.4%) plan for fewer than 100 participants.
-
Breast Cancer research is mostly interventional.
1,015 interventional and 236 observational studies make up this index (81.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
1,251 total, page 4 of 26
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
IDEAYA Biosciences
NCT05787587
Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer
Brigham and Women's Hospital
NCT04030507
Tumor-Derived FGF19
University of Central Florida
NCT06068257
Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer
National Cancer Institute (NCI)
NCT06253520
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Terremoto Biosciences
NCT07109726
Breast Margin Study: Routine Cavity Shave Margins Vs. Selective Margins Using Savi Scout®
Case Comprehensive Cancer Center
NCT05825482
EXploring Inflammation and Social deTerminants Study in Breast Cancer Patients
Thomas Jefferson University
NCT07478016
Liposomal Bupivacaine Vs Bupivacaine with Dexmedetomidine in Erector Spinae Plane Blocks for Mastectomies
United States Naval Medical Center, Portsmouth
NCT06252662
Nutrition Awareness Among Women With Non-Metastatic Breast Cancer
UNC Lineberger Comprehensive Cancer Center
NCT07389967
Building on Trust: Navigating Preventive Lung, Breast, and Prostate Cancer Screenings at Community Resource Spots
AdventHealth
NCT07231159
Community-led Navigation to Address Disparities in Mammography Among Native American Women
Johns Hopkins Bloomberg School of Public Health
NCT06957535
The MIND-BC Study: MIND Diet for Breast Cancer Cognition
H. Lee Moffitt Cancer Center and Research Institute
NCT07018986
Microbiome and Association With Implant Infections
University of California, San Francisco
NCT05020574
Improving Genetic Counseling for BRCA+ Mothers
Georgetown University
NCT04258280
MIRAI-MRI: Comparing Screening MRI for Patients at High Risk for Breast Cancer Identified by Mirai and Tyrer-Cuzick
University of Massachusetts, Worcester
NCT05968157
Multi-center MRD Registry for Inflammatory Breast Cancer
M.D. Anderson Cancer Center
NCT06966050
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
OnKure
NCT06239467
Chemotherapy-induced Cognitive and Brain Changes in Older Adults With Breast Cancer
Massachusetts General Hospital
NCT02290834
The COMPASSION Study
Dana-Farber Cancer Institute
NCT06507930
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Jazz Pharmaceuticals
NCT06695845
Prospective Breast Cancer Biospecimen Collection
Thomas Jefferson University
NCT04074720
Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer
Olema Pharmaceuticals
NCT05508906
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
Baylor Breast Care Center
NCT05020860
PAS 1ml Magtrace® for Sentinel Lymph Node Biopsy in Breast Cancer Patients
Endomagnetics
NCT06610539
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
Hummingbird Bioscience
NCT06956690
A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer
Memorial Sloan Kettering Cancer Center
NCT07483307
A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast)
National Cancer Institute (NCI)
NCT07067138
Time-Restricted Eating and Cancer: Clinical Outcomes, Mechanisms, and Moderators
Cedars-Sinai Medical Center
NCT04722341
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
University Health Network, Toronto
NCT05592938
ASHBY: Accelerated Super-Hypofractionated Breast Brachytherapy
Virginia Commonwealth University
NCT06185205
IORT Following Breast Conserving Surgery for Early Stage Breast Cancer Registry
Mount Carmel Health System
NCT03536897
IKS014 in Advanced Solid Tumors That Express HER2
Iksuda Therapeutics
NCT05872295
Bupivacaine vs Placebo for Unilateral Mastectomy Surgical Site Post-operative Pain Control
Memorial Sloan Kettering Cancer Center
NCT03351348
Breast Cancer, Reasoning, and Activity Intervention
Mayo Clinic
NCT04816006
HIIT Following Breast Cancer Chemotherapy
University of Florida
NCT05913713
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
Avacta Life Sciences
NCT04969835
Ultrasound Imaging and Spectroscopy as Early Indicators of Locally-Advanced Breast Cancer Response
Sunnybrook Health Sciences Centre
NCT04134780
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
MBrace Therapeutics
NCT07145255
Breast Cancer - Navigate - Prospective Cohort
Northwestern University
NCT06271356
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
Incyclix Bio
NCT05735080
A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
Qurgen
NCT05989724
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
NextCure
NCT06774963
5 vs. 9-day Course of Whole Breast Radiotherapy With Boost for Early-stage Breast Cancer
University of Utah
NCT06961955
Study of Aerobic Training for People Receiving Chemotherapy for Breast Cancer
Memorial Sloan Kettering Cancer Center
NCT05716893
Opioid Dispensing Device for Post-Operative Pain in Cancer Patients
Columbia University
NCT05585788
Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC
University of Kansas Medical Center
NCT05645380
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer
Genentech
NCT07214662
Quantitative MRI Assessment of Breast Cancer Therapy Response
Corewell Health East
NCT05704062
Telehealth Exercise Program Evaluating Fatigue and Physical Function in Rural Cancer Survivors
University of Colorado, Denver
NCT07001241
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
Proton Collaborative Group
NCT01766297
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 235 |
| Phase 2 | 256 |
| Phase 3 | 100 |
| Phase 4 | 20 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
What is open for Breast Cancer right now
423 recruiting of 1,251 indexed (34% open).
Phase mix: 120 late (III/IV) vs 491 early (I/II) (early-phase heavy).
Top sponsor: Memorial Sloan Kettering Cancer Center (98 trials), 9 others listed. 50 shown below, recruiting first. #1 of 28,963 conditions by registered trial count.
How open-enrollment share is computed
Open share is recruiting_count divided by trial_count for this condition label in the public registry export. Status can change between pulls; treat the figure as a snapshot of research attention, not treatment availability.
Frequently Asked Questions
How many clinical trials are there for Breast Cancer?
PlainTrial tracks 1,251 US clinical trials for Breast Cancer, of which 423 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Breast Cancer?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.